In pre-clinical testing, we found that regional delivery of 2G-T (CD28) cells elicited disease eradication in a HN3 xenograft model of head and neck squamous cell carcinoma (HNSCC).42 The gene discussed is CD28; the disease is head and neck squamous cell carcinoma.